To provide an overview of contemporary advances in the treatment of metabolic bone diseases, particularly focusing on osteoporosis and related disorders.
Approach:
Overview of Advances: The editorial discusses recent developments in therapies for metabolic bone diseases, emphasizing the multidimensional nature of skeletal medicine.
Pharmacological Strategies: It focuses on pharmacological strategies targeting bone remodeling and mineral metabolism, including established efficacy of zoledronic acid and insights from FGF23 biology.
Role of Sclerostin: The role of sclerostin in bone formation is examined, leading to the development of anti-sclerostin antibodies as a treatment for osteoporosis.
Mineral Metabolism Optimization: The editorial discusses ongoing investigations of vitamin D analogues, including doxercalciferol, and their potential therapeutic value.
Systemic Determinants of Skeletal Health: It highlights the influence of systemic factors, such as gut microbiota and metabolic surgery, on bone health.
Patient-Centered Outcomes: The importance of patient-reported outcomes and chronic disease burden in treatment efficacy is discussed.
Key Findings:
Zoledronic acid has established antifracture efficacy in osteoporosis.
Burosumab is effective for X-linked hypophosphatemia and tumor-induced osteomalacia.
Anti-sclerostin antibodies represent a significant advancement in osteoporosis therapy.
Doxercalciferol shows potential in preventing bone loss over 24 months.
Gut microbiota dysbiosis is linked to osteoporosis, suggesting a gut–bone axis.
Metabolic surgery affects bone turnover and increases fracture risk.
Interpretation:
The studies reflect a shift in bone research towards mechanism-driven interventions, aiming to translate biological advances into clinical strategies.
Limitations:
Challenges remain in determining optimal treatment duration and sequencing of therapies for osteoporosis and related conditions.
Long-term management strategies for certain metabolic bone diseases are not fully defined.
Conclusion:
The editorial underscores the need for continued innovation in metabolic bone disease treatments, integrating insights from various physiological systems.
Published evidence linked liraglutide and semaglutide to improvements in psoriasis severity, inflammatory markers, and metabolic outcomes, while evidence in psoriatic arthritis remained sparse.
